« Back
Home /
Plerixafor (octahydrochloride)

Plerixafor (octahydrochloride)

Item no.	HY-50912-10mg
Manufacturer	MedChem Express
CASRN	155148-31-5
Amount	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Neuroscience Neural Lineage Markers Neuroinflammation Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	95.80
Citations	[1]Zabel BA, et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 2009 Sep 1;183(5):3204-11.\|[2]Mercurio L, et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res. 2016 Mar 25;35:55.\|[3]Yang J, et al. Continuous AMD3100 Treatment Worsens Renal Fibrosis through Regulation of Bone Marrow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation. PLoS One. 2016 Feb 22;11(2):e0149926.\|[4]Chu PY, et al. CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis. PLoS One. 2015 Jul 27;10(7):e0133616.\|[5]Schols D, et al. HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Res. 2006 Sep;71(2-3):216-26. Adv Funct Mater. 2020, 2000309. Am J Physiol Cell Physiol. 2025 Apr 1;328(4):C1260-C1278. Anticancer Drugs. 2017 Oct;28(9):935-942. Brain Behav Immun. 2017 Jan:59:322-332. J Neuroinflammation. 2025 Jun 28;22(1):169. Mater Today Bio. 2024 Sep 1:28:101222. Mol Ther-Nucl Acids. 2023 Mar 9. Oncogene. 2022 Oct;41(41):4633-4644. Oxid Med Cell Longev. 2021 Aug 2;2021:9993240. Patent. US20190133998A1. Pharmaceutics. 2021 Mar 24;13(4):439. Proc Natl Acad Sci U S A. 2025 Mar 18;122(11):e2425795122. Ruprecht-Karls-University Heidelberg. 2023 Aug 3. ACS Infect Dis. 2023 Nov 10;9(11):2105-2118. Acta Biomater. 2024 Jul 17:S1742-7061(24)00395-7. Acta Biomater. 2024 Mar 15:177:414-430. Acta Pharmacol Sin. 2025 Oct 17. Adv Funct Mater. 2024 Dec 23. Adv Sci (Weinh). 2025 Jun 19:e00225. Andrology. 2023 Feb;11(2):295-306. Bioact Mater. 2021 Jan 7;6(7):2039-2057. Biochem Biophys Res Commun. 2021 Jan 1;534:337-342. Biochem Pharmacol. 2025 Jun:236:116852. Biomaterials. 2025 Jan 3:317:123091. Biomed Pharmacother. 2020 Oct:130:110610. Biomolecules. 2024 Sep 25;14(10):1206. bioRxiv. 2025 Oct 7. BMC Complement Altern Med. 2018 Dec 12;18(1):330. Br J Haematol. 2023 May;201(3):459-469. Cancer Lett. 2022 Oct 7;551:215944. Cardiovasc Res. 2025 Nov 11:cvaf215. Cell Death Dis. 2017 Jan 19;8(1):e2560. Cell Death Dis. 2022 Feb 4;13(2):118. Cell Death Dis. 2023 Mar 28;14(3):219. Cell Death Discov. 2025 Apr 8;11(1):156. Cell Mol Immunol. 2020 Mar;17(3):283-299. Cell Mol Life Sci. 2024 Mar 13;81(1):132. Cell Physiol Biochem. 2018;46(3):890-906. Cell Rep Med. 2025 Jul 15;6(7):102211. Cell Signal. 2020 Feb;66:109488. Cell Tissue Res. 2020 Jun;380(3):469-486. Cell Transplant. 2022 Jan-Dec;31:9636897221129171. Cells. 2019 Jul 22;8(7):761. Cells. 2022 Jan 4;11(1):155. Chem Eng J. 2025 Oct 15. Chinese Journal of Tissue Engineering Research . 2014,18(45): 7327-7332. Drug Des Devel Ther. 2022 Jan 6;16:67-81. Exp Ther Med. 2021 Sep;22(3):1037. Fertil Steril. 2020 May;113(5):1067-1079.e5. Immunity. 2024 Feb 13;57(2):364-378.e9. Int Immunopharmacol. 2024 Nov 30:144:113707. Int J Biol Sci. 2017 May 5;13(5):604-614. Int J Mol Sci. 2023 Aug 13;24(16):12740. Int J Mol Sci. 2024 Jul 1;25(13):7254. Int J Mol Sci. 2024 May 4;25(9):5018. Int J Nanomedicine. 2023 Jul 31:18:4329-4346. Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):23. J Cell Mol Med. 2025 Jan;29(2):e70352. J Diabetes Complications. 2020 Oct;34(10):107654. J Immunother Cancer. 2024 Dec 4;12(12):e009629. J Mater Chem B. 2018 Apr 7;6(13):1951-1964. J Nanobiotechnology. 2025 Aug 29;23(1):592. J Oncol. 2021 Oct 8:2021:5584406. J Periodontol. 2025 Jul 8. J Steroid Biochem Mol Biol. 2021 Sep:212:105926. J Transl Med. 2023 Sep 5;21(1):593. Kaohsiung J Med Sci. 2022 Feb;38(2):120-128. Leukemia. 2025 Aug 15. Ludwig maxime clinic. University of Munich. 2019 Apr. Mol Med Rep. 2020 Oct;22(4):3201-3212. Nano Today. 2022, 47: 101689. Nat Cell Biol. 2024 Aug;26(8):1346-1358. Oncogene. 2019 Jun;38(25):5021-5037. Oncol Lett. 2018 Sep;16(3):3976-3982. Patent. US20200360478A1. Phytomedicine. 2025 Jun:141:156667. PLoS One. 2021 Mar 1;16(3):e0247707. Res Sq. 2025 Aug 07. Res Sq. 2025 Mar 16. Research Square Preprint. 2021 Aug. Research Square Preprint. 2022 Jul. Research Square Preprint. 2023 Oct 23. SSRN. 2025 Jan 13. SSRN. 5 Feb 2022. Stem Cell Res Ther. 2022 Feb 23;13(1):79. Stem Cells Int. 2020 Jul 7;2020:1498315. Theranostics. 2021 Jan 1;11(6):2612-2633. Transl Stroke Res. 2022 Apr;13(2):276-286. Universität Hamburg. Informatics and Natural Sciences. 2021 Mar 19. University of Zagreb. 2024 May 23. Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.
Smiles	[H]Cl.N1(CCCNCCNCCCNCC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.[8]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AMD3100 (octahydrochloride),JM3100 (octahydrochloride),SID791 (octahydrochloride)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	CXCR; HIV; Virus Protease
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	794.47
Product Description	Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
Manufacturer - Research Area	Inflammation/Immunology; Endocrinology; Cancer
Solubility	DMSO : < 1 mg/mL\|H2O : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; GPCR/G Protein; Immunology/Inflammation
Clinical information	Launched
Isoform	CXCR4; CXCR7; HIV-1; HIV-2
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.